In the first six months of 2026, Abbott granted 2,000,814 stock options, 449,237 restricted stock awards, and 4,999,652 restricted stock units under its incentive stock program. At June 30, 2026, approximately 140 million shares were reserved for future grants. This reserve reflects the shares authorized by Abbott's shareholders in April 2026. Information regarding the number of options outstanding and exercisable at June 30, 2026, is as follows:


	Outstanding		Exercisable
Number of shares	22,967,126		19,455,098
Weighted average remaining life (years)	4.7		3.9
Weighted average exercise price	$	95.21	$	90.62
Aggregate intrinsic value (in millions)	$	227	$	227

In connection with the completion of the Exact Sciences acquisition, unvested Exact Sciences restricted stock units were converted into Abbott restricted stock units, in accordance with the merger agreement. The number of restricted stock units converted was 1,476,916 at a fair value of $105.62.

The total unrecognized share-based compensation cost at June 30, 2026, amounted to $774 million, which is expected to be recognized over approximately the next three years.